Cancer Treatment Reviews
Volume 29 , Pages 11-19 , May 2003

The tumor microenvironment: focus on myeloma

  • William S Dalton

      Affiliations

    • Corresponding Author InformationCorrespondence to: William S. Dalton, PhD, MD, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. Tel.: 1-813-615-4257; Fax: 1-813-615-4258

References 

  1. Hazlehurst LA, Foley NE, Gleason-Guzman MC, et al.  Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 1999;59(5):1021–1028
  2. Grogan TM, Spier CM, Salmon SE, et al.  P-Glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993;81(2):490–495
  3. Dalton WS, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin. Oncol. 1999;26(5 Suppl. 13):23–27
  4. Dalton WS, Grogan TM, Meltzer PS, et al.  Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 1989;7(4):415–424
  5. Sonneveld P, Marie JP, Huisman C, et al.  Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia. 1996;10(11):1741–1750
  6. Abbaszadegan MR, Foley NE, Gleason-Guzman MC, Dalton WS. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. Int. J. Cancer. 1996;66(4):506–514
  7. Linsenmeyer ME, Jefferson S, Wolf M, et al.  Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br. J. Cancer. 1992;65(3):471–475
  8. Chauhan D, Pandey P, Hideshima T, et al.  SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem. 2000;275(36):27845–27850
  9. Durand RE, Sutherland RM. Effects of intercellular contact on repair of radiation damage. Exp. Cell Res. 1972;71(1):75–80
  10. Sethi T, Rintoul RC, Moore SM, et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999;5(6):662–668
  11. Hoyt DG, Rusnak JM, Mannix RJ, et al.  Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res. 1996;56(18):4146–4149
  12. Oloumi A, MacPhail SH, Johnston PJ, et al.  Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res. 2000;60(20):5747–5753
  13. St Croix B, Florenes VA, Rak JW, et al.  Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 1996;2(11):1204–1210
  14. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science. 1995;267(5199):891–893
  15. Wartenberg M, Donmez F, Ling FC, et al.  Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. FASEB J. 2001;15(6):995–1005
  16. Teicher BA, Herman TS, Holden SA, et al.  Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990;247(4949 Pt 1):1457–1461
  17. Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 1997;57(12):2388–2393
  18. Meredith JE, Schwartz MA. Integrins, adhesion and apoptosis. Trends Cell Biol. 1997;7:146–151
  19. Vizirianakis IS, Chen YQ, Kantak SS, et al.  Dominant-negative E-cadherin alters adhesion and reverses contact inhibition of growth in breast carcinoma cells. Int. J. Oncol. 2002;21(1):135–144
  20. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol. Biol. Cell. 1993;4(9):953–961
  21. Assoian RK. Anchorage-dependent cell cycle progression. J. Cell Biol. 1997;136(1):1–4
  22. St Croix B, Sheehan C, Rak JW, et al.  E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol. 1998;142(2):557–571
  23. Rodeck U, Jost M, DuHadaway J, et al.  Regulation of Bcl-xL expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA. 1997;94(10):5067–5072
  24. Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc. Natl. Acad. Sci. USA. 1995;92(13):6161–6165
  25. Folkman J, Moscona A. Role of cell shape in growth control. Nature. 1978;273(5661):345–349
  26. Lagneaux L, Delforge A, Bron D, et al.  Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998;91(7):2387–2396
  27. Damiano JS, Cress AE, Hazlehurst LA, et al.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93(5):1658–1667
  28. Higashimoto I, Chihara J, Kakazu T, et al.  Regulation of eosinophil cell death by adhesion to fibronectin. Int. Arch. Allergy Immunol. 1996;111(Suppl. 1):66–69
  29. Zaitseva MB, Mojcik CF, Salomon DR, et al.  Co-ligation of alpha4beta1 integrin and TCR rescues human thymocytes from steroid-induced apoptosis. Int. Immunol. 1998;10(10):1551–1561
  30. de la Fuente MT, Casanova B, Garcia-Gila M, et al.  Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia. 1999;13(2):266–274
  31. Meyer N, Duensing S, Anastassiou G, et al.  Altered expression of beta 1 integrins in renal carcinoma cell lines exposed to vinblastine. Anticancer Res. 1999;19(2C):1509–1512
  32. Hikawa T, Mori T, Abe T, Hori S. The ability in adhesion and invasion of drug-resistant human glioma cells. J. Exp. Clin. Cancer Res. 2000;19(3):357–362
  33. Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J. Cell Biol. 2001;152(3):633–643
  34. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma. 2000;38(1–2):71–81
  35. Hazlehurst LA, Damiano JS, Buyuksal I, et al.  Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000;19(38):4319–4327
  36. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 2001;15(8):1232–1239
  37. Hazlehurst LA, Valkov N, Wisner L, et al.  Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 2001;98(6):1897–1903
  38. Anderson KC. Plasma cell tumors. In:  Bast RC,  Kufe DW,  Pollack RE,  Weichselbaum RR,  Holland JR,  Frei E,  Gansler TS editor. Cancer medicine. 5th ed.. Hamilton, Ont: BC Decker; 2001;p. 2066–2085
  39. Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr. Opin. Oncol. 2000;12(6):557–563
  40. Kawano MM, Huang N, Tanaka H, et al.  Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules. Br. J. Haematol. 1991;79(4):583–588
  41. Uchiyama H, Barut BA, Mohrbacher AF, et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82(12):3712–3720
  42. Gimble JM, Pietrangeli C, Henley A, et al.  Characterization of murine bone marrow and spleen-derived stromal cells: analysis of leukocyte marker and growth factor mRNA transcript levels. Blood. 1989;74(1):303–311
  43. Hideshima T, Chauhan D, Schlossman R, et al.  The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20(33):4519–4527
  44. Dankbar B, Padro T, Leo R, et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor–stromal cell interactions in multiple myeloma. Blood. 2000;95(8):2630–2636
  45. Urashima M, Chauhan D, Uchiyama H, et al.  CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 1995;85(7):1903–1912
  46. Lacy MQ, Donovan KA, Heimbach JK, et al.  Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 1999;93(1):300–305
  47. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet. 2000;355(9200):248–250
  48. Hardin J, MacLeod S, Grigorieva I, et al.  Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84(9):3063–3070
  49. Chauhan D, Kharbanda S, Ogata A, et al.  Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89(1):227–234
  50. Thomas X, Anglaret B, Magaud JP, et al.  Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk. Lymphoma. 1998;32(1–2):107–119
  51. Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs. 1995;49(1):11–19
  52. Dingemans AM, Witlox MA, Stallaert RA, et al.  Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin. Cancer Res. 1999;5(8):2048–2058
  53. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 2002;168(5):2544–2553
  54. Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449–1456
  55. Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355–365
  56. Kischkel FC, Hellbardt S, Behrmann I, et al.  Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14(22):5579–5588
  57. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J. Biol. Chem. 1993;268(15):10932–10937
  58. Wang MW, Consoli U, Lane CM, et al.  Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ. 1998;9(2):105–112
  59. Koopman G, Keehnen RM, Lindhout E, et al.  Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J. Immunol. 1994;152(8):3760–3767
  60. Tillman DM, Petak I, Houghton JA. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin. Cancer Res. 1999;5(2):425–430
  61. Fulda S, Friesen C, Los M, et al.  Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 1997;57(21):4956–4964
  62. Fulda S, Strauss G, Meyer E, Debatin KM. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood. 2000;95(1):301–308
  63. Landowski TH, Shain KH, Oshiro MM, et al.  Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood. 1999;94(1):265–274
  64. Shain KH, Landowski TH, Buyuksal I, et al.  Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia. 2000;14(5):830–840
  65. Landowski TH, Qu N, Buyuksal I, et al.  Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997;90(11):4266–4270
  66. Catlett-Falcone R, Landowski TH, Oshiro MM, et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105–115
  67. Read MA, Neish AS, Luscinskas FW, et al.  The proteasome pathway is required for cytokine-induced endothelial- leukocyte adhesion molecule expression. Immunity. 1995;2(5):493–506
  68. Hideshima T, Richardson P, Chauhan D, et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071–3076
  69. Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, Teixido J. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br. J. Haematol. 1999;107(4):825–834
  70. Robledo MM, Sanz-Rodriguez F, Hidalgo A, Teixido J. Differential use of very late antigen-4 and -5 integrins by hematopoietic precursors and myeloma cells to adhere to transforming growth factor-beta1-treated bone marrow stroma. J. Biol. Chem. 1998;273(20):12056–12060
  71. Ridley RC, Xiao H, Hata H, et al.  Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81(3):767–774

PII: S0305-7372(03)00077-X

doi: 10.1016/S0305-7372(03)00077-X

Cancer Treatment Reviews
Volume 29 , Pages 11-19 , May 2003

Article Tools

* Image Usage & Resolution